MedTrace Logo

A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001)

NCT00877448 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2023-03-07

Study results available
· View outcomes & findings →

Summary

A phase I/II, randomized, single-blind, placebo-controlled escalating double-dose safety study of an intramuscular universal influenza vaccine (Multimeric-001) injected to healthy volunteers.

Conditions

  • Healthy

Interventions

BIOLOGICAL

Adjuvanted Multimeric-001 250 Mcg

BIOLOGICAL

Multimeric-001 250 Mcg

BIOLOGICAL

Phosphate Buffered saline

BIOLOGICAL

Adjuvanted PBS

BIOLOGICAL

Adjuvanted Multimeric-001 500 Mcg

BIOLOGICAL

Multimeric-001 500 Mcg

BIOLOGICAL

Multimeric-001 125 Mcg

Sponsors & Collaborators

  • BiondVax Pharmaceuticals ltd.

    lead INDUSTRY

Principal Investigators

  • Jacob Atsmon, MD · Sourasky Medical Center, Tel Aviv, Israel

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2009-10-31
Completion
2009-11-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00877448 on ClinicalTrials.gov